Imunon Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Minimum Stockholders' Equity Requirement

Reuters
2025/05/20
Imunon Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Minimum Stockholders' Equity Requirement

Imunon Inc. has announced that it received a notice from The Nasdaq Stock Market LLC on May 19, 2025, indicating non-compliance with the minimum stockholders' equity requirement necessary for continued listing on The Nasdaq Capital Market. The company failed to meet Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2.5 million or adherence to alternative compliance standards. Imunon has until July 3, 2025, to submit a compliance plan, and if accepted, may receive up to 180 days for remediation. The notice does not immediately affect the trading of Imunon's common stock under the symbol "IMNN". Imunon is currently evaluating options to regain compliance but acknowledges there is no guarantee of meeting the requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-011601), on May 20, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10